EFFECTS OF INTRAVENOUS SM-9527 (DOUBLE-CHAIN TISSUE PLASMINOGEN-ACTIVATOR) ON LEFT-VENTRICULAR FUNCTION IN THE CHRONIC STAGE OF ACUTE MYOCARDIAL-INFARCTION

Clinical effects of thrombolytic agent SM-9527 (double-chain tissue pl asminogen activator) on left ventricular (LV) function were assessed i n patients with acute myocardial infarction (AMI). A dose of 30 X 10(6 ) IU SM-9527 was given intravenously to patients with AMI within 6 h a fter onset. Of 159 candidates, 20 were excluded from the trial due to diseases other than myocardial infarction or failure to meet the proto col requirements; 114 of the remaining 139 were subjected to LV functi on analysis. The following results were obtained: (1) Patients with su ccessful reperfusion in response to SM-9527 in the acute stage without later reocclusion revealed a significant improvement of LV function i n the chronic stage. (2) Adverse effects were noted in 15 patients (10 .8%), but none were serious; all were bleeding related to catheterizat ion. (3) Hemagglutination fibrinolysis system test revealed no problem s. It is concluded that early thrombolytic therapy with intravenous SM -9527 for AMI provides significant improvement of LV function in the c hronic stage.